Dr. Mark Atkinson presented on endogenous stem cell mobilization using botanical supplements from StemRogen, focusing on their core product StemRogen Release. He explained how stem and progenitor cells are mobilized from the bone marrow in response to tissue damage and discussed the Load Repair Model of Health and Disease, emphasizing the importance of both reducing external stressors and enhancing endogenous repair capacity. Dr. Atkinson shared clinical case studies including patients with coronary artery disease, chronic heart failure, and Parkinson’s disease who showed improvements in symptoms and functional measures when taking StemRogen products. He also introduced two additional products – StemRogen Mobilize for microcirculation support and StemRogen Signal for reducing inflammation – and outlined how practitioners can integrate these supplements into existing treatment protocols. The presentation concluded with a discussion of practical applications and questions from attendees about using the products for cancer support and long COVID treatment.
Endogenous Stem Cell Systems Presentation
Dr. Mark Atkinson, a British medical doctor specializing in integrative functional medicine, introduced a presentation on endogenous stem cell systems and their mobilization using botanicals. He explained his background and mentioned his experience with the StemRogen product, which helped him recover from chronic tendinopathy. The presentation was planned to cover the basics of endogenous stem cells, the Load Repair Model of Health and Disease, a new perspective on atherosclerosis, and methods to assess patients’ repair capacity.
StemRogen Release Product Overview
Mark introduced the StemRogen Release product and outlined his presentation, which would cover case studies, pilot trials, and strategies for addressing limitations in stem cell effectiveness. He explained the fundamental properties of stem cells, including their ability to self-renew and differentiate into other cells, and discussed the role of progenitor cells in blood and immune cell creation. Mark also introduced tissue-resident stem cells and circulating stem and progenitor cells, noting that the latter originate in the bone marrow and can be tracked using the CD system through flow cytometry.
Stem Cell Mobilization Stages
Mark explained the three fundamental stages of stem cell mobilization: tissue repair demand signals, amplification and coordination, and marrow niche response. He described how damaged or stressed cells release signals like hypoxia-induced factor and vascular endothelial growth factor, which weaken retention signals in the bone marrow, allowing stem and progenitor cells to enter circulation. Mark explained that these circulating cells act as coordinators and catalysts of tissue-level responses, releasing chemokines, growth factors, and exosomes that reprogram immune and stromal cells to support healing and inflammation resolution.
Disease Progression Framework Presentation
Mark presented a framework for understanding disease progression based on the relationship between load and repair capacity in the body. He explained that health can be defined as the body’s ability to adapt to change and maintain function over time, shaped by these two fundamental dynamics. Mark emphasized the importance of both reducing load and enhancing endogenous repair capacity, particularly through mobilizers that increase circulating stem and progenitor cells.
Endogenous Vascular Repair Mechanisms
Mark discussed a 2008 paper that reframed atherosclerosis as a failure of endogenous vascular repair rather than solely as a cholesterol and inflammation issue. He explained how the load-repair model considers both external factors (like APOB lipoproteins) and internal repair capacity, emphasizing the importance of enhancing endogenous repair mechanisms. Mark presented evidence showing a strong correlation between circulating stem progenitor cells and vascular disease, noting that lower numbers of these cells are associated with higher cardiovascular risk and worse outcomes in conditions like diabetic complications and stroke.
Stem Cell Repair Product Discussion
Mark discussed the decline in endogenous repair capacity in patients in their 40s and 50s, highlighting symptoms such as delayed wound healing and reduced energy. He introduced Christian Drepo, a stem cell scientist and founder of StemRegen, who developed a product called Stem Regen Release. The product contains seven core ingredients, including AFA (blue-green algae), sea buckthorn extract, and Panax Notar Ginseng, which are known to support stem cell mobilization. Mark noted that StemRegen has invested significantly in pilot clinical trials to demonstrate the impact of these ingredients on stem cells.
StemRogen Research and Ingredients
Mark presented research on StemRogen’s ingredients, including AFA (blue-green algae extract) which showed a 25% increase in stem and progenitor cells, and C buckthorn extract which mobilizes different lineages of stem cells. He highlighted Stemolog (aloe extract) which resulted in an 80% increase in stem progenitor cells. Mark explained that two capsules of StemRogen Release are estimated to mobilize more than 10 million circulating stem progenitor cells within 2 hours, though the actual number is likely double that. The presentation was about to transition to sharing case studies from StemRogen.
STEM Regen Release Integration
Mark discussed the potential integration of STEM regen release into medical protocols for patients with degeneration-related diseases. He presented a case study of a 60-year-old male with coronary artery disease who showed marked functional improvement after following an accelerated protocol involving STEM regen release. Mark also mentioned a pilot study involving 10 patients with chronic heart failure, which demonstrated significant improvements in left ventricular ejection fraction, reduced cardiac stress markers, and decreased symptom burden after six months of treatment with the same protocol.
Parkinson’s StemRogen Study Results
Mark presented a case study of a Parkinson’s disease patient who experienced significant symptom improvement after taking the StemRogen release accelerator protocol, including reduced tremor, improved gait, and better dressing and feeding abilities. He then discussed a six-month pilot study involving seven Parkinson’s patients, which showed improvements in Unified Parkinson’s Disease Rating Score, depression, sleep quality, balance, and quality of life using validated assessment tools. The study results were promising enough to warrant further recruitment for additional participants.
Stem Regen Product Presentation
Mark presented on Stem Regen products, explaining three main products: Stem Regen Release (to mobilize stem cells), Stem Regen Mobilize (to improve microcirculation), and Stem Regen Signal (to reduce inflammation). He discussed how these products can support healing by enhancing endogenous repair capacity, addressing microcirculation constraints, and managing inflammation. Mark also shared a mind-body technique for stress regulation and demonstrated its application. When asked about using Stem Regen with cancer patients, Mark advised against using it during active cancer treatment but noted it could be considered post-treatment as part of a regeneration protocol. The session concluded with information about joining the Stem Regen Practitioner Program for additional educational resources.
